InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.19
(
0.41%
)
Bitcoin
63,857.48
(
0.37%
)
Post# of 253175
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120476
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 198812

Tuesday, 08/30/2016 10:07:03 AM

Tuesday, August 30, 2016 10:07:03 AM

Post# of 253175
KMDA +8% on phase-2 data in AAT deficiency:

http://finance.yahoo.com/news/kamada-meets-primary-endpoint-u-103000805.html

Note: This trial tested inhaled AAT. In a partnership with SHPG, KMDA sells injected AAT with the brand name, Glassia as a treatment for AAT deficiency.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up